Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.

Standardized monitoring workflows and clearer reimbursement support are critical to improving community clinicians’ readiness ...

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and ...

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

Early Intervention: Flagging non-adherence allows for earlier intervention, such as a phone call. This compassionate, ...

Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.

ICHRAs could either stabilize or destabilize ACA risk pools, with adoption patterns raising concerns about access, equity, ...